Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

Tech stocks today: OpenAI strikes deal with Pentagon amid Anthropic feud, Nvidia invests $4B in photonics makers

View original at finance.yahoo.com
Tech stocks today: OpenAI strikes deal with Pentagon amid Anthropic feud, Nvidia invests $4B in photonics makers Artificial intelligence startup OpenAI (OPAI.PVT) said it landed a deal with the Department of Defense over the weekend, coinciding with the US strikes in Iran and coming just after President Trump ordered a…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We don't need it, we don't want it, and will not do business with them again

    80% confidence
  • OpenAI shares Anthropic's red lines on mass surveillance and autonomous weapons

    80% confidence
  • The partnership with OpenAI remains strong and central, with unchanged IP, commercial, revenue-sharing, and AGI processes

    80% confidence
  • DOD has no desire to surveil Americans or develop fully autonomous weapons

    80% confidence
  • CoreWeave capital expenditures will increase from $15.4 billion in 2025 to at least $30 billion in 2026

    80% confidence
  • What we are witnessing is not a temporary squeeze, but a tsunami-like shock originating in the memory supply chain, with ripple effects spreading across the entire consumer electronics industry

    80% confidence
  • Anthropic would rather cut ties with the government than cross two red lines: using models for mass surveillance of US citizens and using them to develop fully autonomous weapons

    80% confidence
  • If Anthropic doesn't get their act together and be helpful during phase-out, will use full power of presidency to make them comply with major civil and criminal consequences

    80% confidence
  • Computing has fundamentally changed in the age of AI, with software running on intelligence with tokens generated in real time by AI factories

    80% confidence
  • Confident in hyperscalers' cash flow growing due to inflection of agentic AI and usefulness of agents across enterprises

    80% confidence
  • Cannot in good conscience accede to Pentagon's request for unrestricted AI model usage

    80% confidence
  • This is a simple, common-sense request that will prevent Anthropic from jeopardizing critical military operations and potentially putting our warfighters at risk

    80% confidence
  • Data Center revenue for Q4 was record $62.3 billion, up 75% year-over-year and 22% sequentially, driven by major platform shifts in accelerated computing and AI

    80% confidence
  • Contract language received overnight from DOD made virtually no progress on preventing Claude's use for mass surveillance or fully autonomous weapons, with legalese allowing safeguards to be disregarded

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Tech stocks today: OpenAI strikes deal with Pentagon amid Anthropic feud, Nvidia invests $4B in photonics makers — Source | Via News | Finance Via News